The 5 most recent market catalysts affecting $BBOT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 60
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27
Leerink Partners, a prominent investment bank, maintained its 'Outperform' rating on BridgeBio Oncology (BBOT), indicating continued confidence in the company's long-term prospects…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 55
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
Raymond James analyst Sean McCutcheon maintained an 'Outperform' rating for BridgeBio Oncology (BBOT), indicating continued positive sentiment towards the company's fundamentals. H…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers
BridgeBio Oncology Therapeutics (BBOT) released new clinical data for its KRASG12C inhibitor BBO-8520, demonstrating a 75% ORR in combination with pembrolizumab in previously treat…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
JP Morgan analyst Priyanka Grover maintained an 'Overweight' rating on BridgeBio Oncology (BBOT) but reduced the price target from $27 to $25. This action signals a slight recalibr…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 95
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
BridgeBio Oncology (BBOT) reported a massive Q2 EPS miss, with losses of $(705.20) per share against an estimate of $(0.57). This represents an astounding 123619.3% miss and a 24.4…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.